Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast to report its first quarter financial results on May 4, 2023, at 8:00 a.m. ET. Investors can join by dialing 833-470-1428 or 929-526-1599 internationally, referencing conference ID 668091, or online via the company’s website. An archived version will be available two hours post-call for 30 days. The company specializes in precision therapies for cancer and blood disorders, focusing on genetic drivers. Blueprint Medicines offers approved treatments such as AYVAKIT® and GAVRETO® and is advancing several programs targeting various cancers. For further details, visit their official website.

Positive

• Supports the company's commitment to transparency with timely financial reporting.
• Engagement in ongoing precision therapy developments, indicating potential for future growth.

Negative

• None.

CAMBRIDGE, Mass., April 20, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 929-526-1599 (international), and refer to conference ID 668091. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines, AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), to patients in the U.S. and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2023-financial-results-on-thursday-may-4-2023-301803558.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines report its first quarter 2023 financial results?

Blueprint Medicines will report its first quarter financial results on May 4, 2023.

How can I access the Blueprint Medicines conference call?

You can access the conference call by dialing 833-470-1428 (domestic) or 929-526-1599 (international) and using conference ID 668091.

What is the focus of Blueprint Medicines Corporation?

Blueprint Medicines focuses on developing precision therapies for cancer and blood disorders.

Where can I find more information about Blueprint Medicines?

More information can be found on the Blueprint Medicines official website at www.BlueprintMedicines.com.